MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cell.2010.02.039

Медицинская библиотека · Cell · 2010

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Van de Veire Sara, Stalmans Ingeborg, Heindryckx Femke, Oura Hajimu, Tijeras-Raballand Annemilaï, Schmidt Thomas, Loges Sonja, Albrecht Imke, Jonckx Bart, Vinckier Stefan, Van Steenkiste Christophe, Tugues Sònia, Rolny Charlotte, De Mol Maria, Dettori Daniela, Hainaud Patricia, Coenegrachts Lieve, Contreres Jean-Olivier, Van Bergen Tine, Cuervo Henar, Xiao Wei-Hong, Le Henaff Carole, Buysschaert Ian, Kharabi Masouleh Behzad, Geerts Anja, Schomber Tibor, Bonnin Philippe, Lambert Vincent, Haustraete Jurgen, Zacchigna Serena, Rakic Jean-Marie, Jiménez Wladimiro, Noël Agnes, Giacca Mauro, Colle Isabelle, Foidart Jean-Michel, Tobelem Gerard, Morales-Ruiz Manuel, Vilar José, Maxwell Patrick, Vinores Stanley A, Carmeliet Geert, Dewerchin Mieke, Claesson-Welsh Lena, Dupuy Evelyne, Van Vlierberghe Hans, Christofori Gerhard, Mazzone Massimiliano, Detmar Michael, Collen Désiré, Carmeliet Peter

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

Для цитирования: Van de Veire Sara, Stalmans Ingeborg, Heindryckx Femke, Oura Hajimu, Tijeras-Raballand Annemilaï, Schmidt Thomas, Loges Sonja, Albrecht Imke, Jonckx Bart, Vinckier Stefan, Van Steenkiste Christophe, Tugues Sònia, Rolny Charlotte, De Mol Maria, Dettori Daniela, Hainaud Patricia, Coenegrachts Lieve, Contreres Jean-Olivier, Van Bergen Tine, Cuervo Henar, Xiao Wei-Hong, Le Henaff Carole, Buysschaert Ian, Kharabi Masouleh Behzad, Geerts Anja, Schomber Tibor, Bonnin Philippe, Lambert Vincent, Haustraete Jurgen, Zacchigna Serena, Rakic Jean-Marie, Jiménez Wladimiro, Noël Agnes, Giacca Mauro, Colle Isabelle, Foidart Jean-Michel, Tobelem Gerard, Morales-Ruiz Manuel, Vilar José, Maxwell Patrick, Vinores Stanley A, Carmeliet Geert, Dewerchin Mieke, Claesson-Welsh Lena, Dupuy Evelyne, Van Vlierberghe Hans, Christofori Gerhard, Mazzone Massimiliano, Detmar Michael, Collen Désiré, Carmeliet Peter. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.. Cell. 2010. DOI: 10.1016/j.cell.2010.02.039.

Предметные рубрики MeSH

Angiogenesis InhibitorsAnimalsAntibodies, MonoclonalCarcinoma, HepatocellularChoroidDisease Models, AnimalEye DiseasesHumansLiver Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicNeovascularization, PhysiologicPapillomaPlacenta Growth FactorPregnancy ProteinsSkin Neoplasms
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.